country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-147125

Copy Link Print Information

DDO-6600

Name: DDO-6600
Brand: MedChemExpress
SKU: HY-147125
Price: 500.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

DDO-6600 is a covalent Hsp90α inhibitor. DDO-6600 allosterically disrupts the Hsp90-Cdc37 interaction. DDO-6600 promotes Apoptosis and the degradation of Cdc37-dependent kinase client proteins (Cdc37-dependent kinase client proteins include AKT and CDK4). DDO-6600 can be used in research on colon cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 98.19%
CAS. Nr.: 2640292-37-9
Formel: C₂₆H₂₈N₄O₂
Molecular Weight:428.53

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

DDO-6600 Chemical Structure

CAS. Nr.: 2640292-37-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[3]

HSP90α

Akt

CDK4

Alle HSP Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle CDK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC50	7.83 μM	Antiproliferative activity against human HCT-116 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs. Antiproliferative activity against human HCT-116 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.	40310691
HCT-116	IC50	25.06 μM	Antiproliferative activity against Cdc37-knockout HCT-116 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs. Antiproliferative activity against Cdc37-knockout HCT-116 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.	40310691
HT-29	IC50	10.21 μM	Antiproliferative activity against human HT-29 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs. Antiproliferative activity against human HT-29 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.	40310691
SK-BR-3	IC50	13.92 μM	Antiproliferative activity against human SKBR-3 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs. Antiproliferative activity against human SKBR-3 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.	40310691
MCF7	IC50	12.17 μM	Antiproliferative activity against human MCF-7 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs. Antiproliferative activity against human MCF-7 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.	40310691
HT-1080	IC50	14.77 μM	Antiproliferative activity against human HT-1080 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs. Antiproliferative activity against human HT-1080 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.	40310691
CT26	IC50	9.24 μM	Antiproliferative activity against mouse CT-26 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs. Antiproliferative activity against mouse CT-26 cells assessed as viability reduction by MTT assay incubated 24, 48, or 72 hrs.	40310691

In Vitro

Anti-cancerOthers

Anti-cancer

DDO-6600 (24-72 h) inhibits HCT-116 cell proliferation with an IC₅₀ of 7.83 μM, while it shows lower potency in Cdc37-KO HCT-116 cells (25.06 μM)^[3].

Others

DDO-6600 (100 μM; incubated with Hsp90 for 1 h) disrupts the Hsp90-Cdc37 interaction in a cell-free HTRF assay, with an inhibition rate of 62.85% at 100 μM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-cancer

DDO-6600 (30 mg/kg; i.p.; once every 2 days; 14 days) serves as a positive control for DDO-6691 (HY-176404) administration in HCT-116 xenograft tumor mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c nude (female, 6 weeks old)^[3]
Dosage:

30 mg/kg
Administration:

intraperitoneal; every 2 days; 14 days
Result:

DDO-6691 reduced tumor volume relative to vehicle by day 26.
DDO-6691 decreased CDK4 and did not increase Hsp90 or Hsp70.

Related Protocols :

Chemical Information

CAS. Nr. 2640292-37-9
Appearance Solid
Molecular Weight 428.53
Formel C₂₆H₂₈N₄O₂
Color White to off-white
SMILES

O=C(N1C(CCCC1)C(N)=O)/C=C/C2=CN(C3=CC=CC=C3)N=C2C4=CC(C)=C(C=C4)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rouges C, et al. Is the C-terminal domain an effective and selective target for the design of Hsp90 inhibitors against Candida yeast?. Microorganisms. 2023 Nov 22;11(12):2837.

[2]. Liu Y, et al. Targeted Covalent Inhibition: A Prospective Way to Develop Novel HSP90 C-terminal Inhibitor. Current Drug Targets. 2022 Dec 1;23(16):1454-6. [Content Brief]

[3]. Feng ZW, et al. Structural Optimization of Pyrazole Compounds as Hsp90 Regulators with Enhanced Antitumor Activity. Journal of medicinal chemistry. 2025 May 22;68(10):9886-9905. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

DDO-6600

Alle HSP Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle CDK Isoform-spezifische Produkte anzeigen